Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Brooks Laboratories Ltd (BROOKS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533543 NSE: BROOKS Pharmaceuticals & Drugs | Small Cap | Brooks Laboratories Share Price
₹66.15 3.15 (5.00%)
As on 13-Aug'26 16:59
Brooks Laboratories Ltd (BROOKS)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 533543 NSE: BROOKS Pharmaceuticals & Drugs | Small Cap | Brooks Laboratories Share Price
₹66.15 3.15 (5.00%)
As on 13-Aug'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹195 Cr.
Current Price
₹66.2
52-Week Low / High
₹37 / 166
TTM EPS
₹2
TTM Sales
₹85.7 Cr.
Book Value per Share
₹41
P/E Ratio
33.57
Higher than its 5-year historical median
Industry PE
53.4
Price to Book (P/B)
1.61
Lower than its 5-year historical median
Price to Sales (P/S)
2.27
Lower than its 5-year historical median
EV/EBITDA
23.64
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
4.92%
Underperforms industry median
Return on Capital Employed (ROCE)
5.33%
Underperforms industry median
Return on Assets (ROA)
4.04%
Operating Profit Margin
1.7%
Net Profit Margin
6.77%
Gross Profit Margin
8.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
3.86%
Operating Profit Growth (1 Year)
-
415.33%
Net Profit Growth (1 Year)
-
90.49%
Asset Quality
Promoter Holding
52.62%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹91 Cr.
Equity
₹29.5 Cr.
Face Value
₹10
All Time Low / High
₹10.32 / 202.80
Check Before You Invest
Quality
Locked
Login to view analysis.
Valuation
Locked
Login to view analysis.
Price Trend
Locked
Login to view analysis.
Is Brooks Laboratories Ltd a good quality company?
Brooks Laboratories Ltd is a weak quality company, based on a inconsistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Brooks Laboratories Ltd performance compare with that of its Peers?
Revenue growth of Brooks Laboratories Ltd vs industry peers?
Brooks Laboratories Ltd revenue CAGR is 3.45%, compared to the industry median CAGR of 5.68%, indicating slower growth and losing its market share.
Promoter shareholding and pledge status of Brooks Laboratories Ltd?
Promoters hold 52.62% of the Brooks Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Brooks Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of -3.3% based on the current price.
10 Year X-Ray : Login to view analysis.
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Brooks Laboratories Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good
Value Creation ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 9.7% | 2.6% | -10.6% | -8.6% | -7.8% | -5.2% | 1.9% | -11.2% | 3.5% | 4.4% | - |
| Value Creation Index ⓘ | -0.3 | -0.8 | -1.8 | -1.6 | -1.6 | -1.4 | -0.9 | -1.8 | -0.8 | -0.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 80 | 57.5 | 55.7 | 55 | 69.7 | 77.3 | 77 | 55.5 | 79.5 | 82.6 | 86 |
| Sales YoY Gr. | - | -28.1% | -3.2% | -1.2% | 26.6% | 10.9% | -0.4% | -27.8% | 43.1% | 3.9% | - |
| Adj EPS ⓘ | 5.4 | 0.9 | -7.1 | -7.7 | -9.4 | -6.3 | 0.1 | -3.3 | 0.5 | 1 | 2 |
| YoY Gr. | - | -84.3% | -929.4% | NA | NA | NA | NA | -2435.7% | NA | 85.2% | - |
| BVPS (₹) ⓘ | 62.3 | 65.4 | 58.4 | 50.8 | 39.5 | 25.7 | 26.1 | 22.8 | 26.5 | 39.1 | 41 |
| Adj Net Profit ⓘ | 10.6 | 1.7 | -13.8 | -15.1 | -23.4 | -15.7 | 0.3 | -8.2 | 1.4 | 2.9 | 6 |
| Cash Flow from Ops. ⓘ | 8.1 | 9.6 | -6.2 | -5.1 | -9.4 | -0.9 | 3.1 | 0.6 | -9.8 | 2.6 | - |
| Debt/CF from Ops. ⓘ | 0.7 | 1.4 | -4.5 | -6.2 | -2.9 | -9.3 | 1.6 | 10.3 | -0.5 | 2.3 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 0.4% | 3.5% | 2.4% | 3.9% | ||||
| Adj EPS ⓘ | -17.1% | NA | 92.6% | 85.2% | ||||
| BVPSⓘ | -5.1% | -0.2% | 14.4% | 47.5% | ||||
| Share Price | -3.1% | -11.9% | -12.4% | -58.9% | ||||
Key Financial Parameters ⓘ
| Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 9.1 | 1.3 | -11.4 | -13.7 | -23 | -19.3 | 0.5 | -13.4 | 2.2 | 3.2 | 4.9 |
| Op. Profit Mgn % ⓘ | 13.9 | 8.8 | -16 | -15.2 | -3.7 | 1.3 | 2.4 | -10.4 | 3.9 | 1.7 | 8.2 |
| Net Profit Mgn % ⓘ | 13.2 | 2.9 | -24.8 | -27.4 | -33.6 | -20.3 | 0.4 | -14.7 | 1.8 | 3.6 | 6.8 |
| Debt to Equity ⓘ | 0.1 | 0.1 | 0.2 | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0 |
| Working Cap Days ⓘ | 216 | 227 | 208 | 234 | 206 | 168 | 159 | 226 | 144 | 150 | 78 |
| Cash Conv. Cycle ⓘ | 25 | 2 | 7 | -7 | 7 | 34 | 31 | 29 | 19 | 52 | 33 |
Valuation of Brooks Laboratories - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 58 | 56 | 55 | 70 | 77 | 77 | 56 | 79 | 83 | 86 |
| Operating Expenses ⓘ + | 52 | 65 | 63 | 74 | 76 | 75 | 61 | 76 | 81 | 79 |
| Operating Profit ⓘ | 5 | -9 | -8 | -4 | 1 | 2 | -6 | 3 | 1 | 7 |
| Operating Profit Margin (%) | 8.8% | -16.0% | -15.2% | -5.6% | 1.2% | 2.4% | -10.5% | 3.9% | 1.7% | 8.2% |
| Other Income ⓘ + | 0 | 0 | 3 | 0 | 1 | 1 | 0 | 1 | 4 | 1 |
| Interest ⓘ | 1 | 2 | 3 | 3 | 3 | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 2 | 6 | 6 | 7 | 7 | 1 | 2 | 2 | 2 | 2 |
| Profit Before Tax ⓘ | 2 | -18 | -15 | -14 | -8 | 1 | -8 | 2 | 3 | 6 |
| Tax ⓘ | 1 | -4 | -0 | 11 | 7 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 2 | -14 | -15 | -24 | -16 | 1 | -8 | 2 | 3 | 6 |
| PAT Margin (%) | 2.9% | -24.8% | -26.9% | -35.0% | -20.2% | 0.9% | -14.7% | 1.9% | 3.7% | 6.8% |
| Adjusted EPS (₹) | 0.9 | -7.1 | -7.6 | -9.8 | -6.3 | 0.3 | -3.3 | 0.6 | 1.0 | 2.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 128 | 114 | 100 | 98 | 64 | 65 | 57 | 70 | 115 | 121 | |
| Debt + | 13 | 25 | 28 | 24 | 8 | 5 | 6 | 5 | 6 | 7 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 18 | 27 | 27 | 26 | 13 | 26 | 23 | 15 | 14 | 11 | |
| Others Liabilities ⓘ | -2 | -4 | 2 | 9 | 7 | 8 | 7 | 4 | 6 | 7 | |
| Total Liabilities ⓘ | 158 | 162 | 157 | 158 | 93 | 103 | 92 | 94 | 141 | 146 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 125 | 124 | 117 | 113 | 15 | 15 | 15 | 14 | 14 | 15 | |
| CWIP ⓘ | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | |
| Investments ⓘ | 1 | 1 | 0 | 0 | 47 | 47 | 47 | 47 | 91 | 91 | |
| Inventories | 8 | 11 | 10 | 14 | 12 | 17 | 11 | 10 | 9 | 11 | |
| Trade Receivables | 11 | 10 | 11 | 16 | 10 | 15 | 13 | 16 | 20 | 16 | |
| Cash Equivalents | 2 | 2 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 8 | |
| Others Assets ⓘ | 12 | 13 | 14 | 14 | 8 | 8 | 5 | 7 | 6 | 5 | |
| Total Assets ⓘ | 158 | 162 | 157 | 158 | 93 | 103 | 92 | 94 | 141 | 146 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 10 | -6 | -5 | -9 | -1 | 3 | 1 | -10 | 3 | 9 |
| Cash Flow From Investing Activity ⓘ + | -17 | -5 | 1 | -2 | -1 | 1 | -0 | 0 | -45 | -3 |
| Cash Flow From Financing Activity ⓘ + | 7 | 12 | 6 | 10 | 1 | -4 | -0 | 10 | 42 | 0 |
| Net Cash Flow ⓘ | -0 | 1 | 2 | -2 | -0 | 0 | -0 | 0 | -0 | 7 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 1.33 | -11.38 | -13.83 | -24.62 | -19.17 | 1.03 | -13.44 | 2.42 | 3.31 | 4.92 |
| ROCE (%) | 2.59 | -10.64 | -8.6 | -7.77 | -5.24 | 1.87 | -11.21 | 3.5 | 4.35 | 5.33 |
| Asset Turnover Ratio | 0.41 | 0.36 | 0.35 | 0.44 | 0.62 | 0.78 | 0.57 | 0.85 | 0.7 | 0.6 |
| PAT to CFO Conversion(x) | 5 | N/A | N/A | N/A | N/A | 3 | N/A | -5 | 1 | 1.5 |
| Working Capital Days | ||||||||||
| Receivable Days | 83.30 | 66.90 | 71.60 | 70.70 | 59.40 | 58.40 | 91.30 | 66.80 | 80.30 | 76.90 |
| Inventory Days | 40.50 | 61.30 | 71.20 | 62.40 | 61.80 | 68.70 | 91.70 | 48 | 41.60 | 43.10 |
| Payable Days | 169.60 | 208.60 | 248.90 | 207.30 | 150.70 | 144.90 | 221.60 | 125.10 | 98.10 | 89.60 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Brooks Laboratories Ltd FAQs
The current trading price of Brooks Laboratories on 13-Aug-2026 16:59 is ₹66.15.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Aug-2026 the market cap of Brooks Laboratories stood at ₹194.9 Cr
The latest P/E ratio of Brooks Laboratories as of 12-Aug-2026 is 33.57.
The latest P/B ratio of Brooks Laboratories as of 12-Aug-2026 is 1.61.
The 52-week high of Brooks Laboratories is ₹165.9 and the 52-week low is ₹36.90.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Brooks Laboratories is ₹85.74 ( Cr.) .
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Brooks Laboratories Ltd is a below average quality company.
The key valuation ratios of Brooks Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Brooks Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
About Brooks Laboratories Ltd
The Company was originally incorporated as Brooks Laboratories Limited on January 23, 2002. Company was initially promoted for manufacturing of latest molecules in Injectables, tablets and dry syrups for the domestic customers. The Company set up a facility for manufacturing Tablets, Dry Syrup and Injectables, which was supported by a research and development centre at Baddi, Himachal Pradesh. The Company started its commercial production in the month of June 2006 and became profitable from the very first year of its production.
The company has set up a well equipped manufacturing unit at Baddi, Himachal Pradesh in the year 2006 and has been awarded a G.M.P Certification for following Good Manufacturing Practices under “Revised Schedule M†of Drugs & Cosmetics Rules, 1945 in respect of various categories of Tablets, Capsules, Liquid Orals, Dry Syrups, SVP (Liquid & Dry) and Ophthalmic Section by The Health & Family Welfare Department, Himachal.
Company’s manufacturing facility at Baddi is capable of manufacturing products confirming to TRS 908 of 2003 (WHO GMP) standards. Its Quality Management System at the factory at Baddi is certified as complying to ISO 9001:2008.
Product of the company
The company has wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General dry powder Injectables, Ampoules and Liquid vials. These products are manufactured in accordance with highest international standards in facilities as per norms of WHO-GMP & ISO 9000-2008.
Some of the product categories are:
- Beta Lactum
- Cephalosporins
- Carbapenems
- General Injectable (Dry Powder)
- General Injectable (Liquid)
- Cortico Steroids
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
